87 related articles for article (PubMed ID: 36909341)
1. Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.
Waddell T; Namburete A; Duckworth P; Fichera A; Telford A; Thomaides-Brears H; Cuthbertson DJ; Brady M
Front Endocrinol (Lausanne); 2023; 14():1063882. PubMed ID: 36909341
[TBL] [Abstract][Full Text] [Related]
2. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
3. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes.
Levelt E; Pavlides M; Banerjee R; Mahmod M; Kelly C; Sellwood J; Ariga R; Thomas S; Francis J; Rodgers C; Clarke W; Sabharwal N; Antoniades C; Schneider J; Robson M; Clarke K; Karamitsos T; Rider O; Neubauer S
J Am Coll Cardiol; 2016 Jul; 68(1):53-63. PubMed ID: 27364051
[TBL] [Abstract][Full Text] [Related]
4. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
[TBL] [Abstract][Full Text] [Related]
5. Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Raverdy V; Chatelain E; Lasailly G; Caiazzo R; Vandel J; Verkindt H; Marciniak C; Legendre B; Bauvin P; Oukhouya-Daoud N; Baud G; Chetboun M; Vantyghem MC; Gnemmi V; Leteurtre E; Staels B; Lefebvre P; Mathurin P; Marot G; Pattou F
Obesity (Silver Spring); 2023 Dec; 31(12):3066-3076. PubMed ID: 37987186
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease.
Si J; Lee G; You HJ; Joo SK; Lee DH; Ku BJ; Park S; Kim W; Ko G
Comput Struct Biotechnol J; 2021; 19():5920-5930. PubMed ID: 34849196
[TBL] [Abstract][Full Text] [Related]
7. The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data.
Fishman J; Tapper EB; Dodge S; Miller K; Lewandowski D; Bogdanov A; Bonafede M
Curr Med Res Opin; 2023 Nov; 39(11):1425-1429. PubMed ID: 37740457
[TBL] [Abstract][Full Text] [Related]
8. Impact of Liver Transplantation on Adipose Tissue Compartments and Its Association With Metabolic Sequela.
Hassouneh R; Flynn S; Shen S; Tseng M; Bui AT; Pham J; Park D; Matherly S; Bruno D; Lee S; Kumaran V; Patel V; Muthiah M; Sharma A; Siddiqui MS
Transplantation; 2024 Jan; 108(1):235-241. PubMed ID: 37439776
[TBL] [Abstract][Full Text] [Related]
9. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.
Vreman RA; Goodell AJ; Rodriguez LA; Porco TC; Lustig RH; Kahn JG
BMJ Open; 2017 Aug; 7(8):e013543. PubMed ID: 28775179
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review.
Aldossari KK
Afr Health Sci; 2023 Jun; 23(2):509-518. PubMed ID: 38223606
[TBL] [Abstract][Full Text] [Related]
11. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.
Gastaldelli A; Cusi K
JHEP Rep; 2019 Oct; 1(4):312-328. PubMed ID: 32039382
[TBL] [Abstract][Full Text] [Related]
12. Digital Twin-Enabled Personalized Nutrition Improves Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes: Results of a 1-Year Randomized Controlled Study.
Joshi S; Shamanna P; Dharmalingam M; Vadavi A; Keshavamurthy A; Shah L; Mechanick JI
Endocr Pract; 2023 Dec; 29(12):960-970. PubMed ID: 37778441
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease is associated with brain function disruption in type 2 diabetes patients without cognitive impairment.
Li X; Zhang W; Bi Y; Chen J; Fu L; Zhang Z; Chen Q; Zhang X; Zhu Z; Zhang B
Diabetes Obes Metab; 2024 Feb; 26(2):650-662. PubMed ID: 37961040
[TBL] [Abstract][Full Text] [Related]
14. Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop.
Peters HPF; Schrauwen P; Verhoef P; Byrne CD; Mela DJ; Pfeiffer AFH; Risérus U; Rosendaal FR; Schrauwen-Hinderling V
J Nutr Sci; 2017; 6():e15. PubMed ID: 28630692
[TBL] [Abstract][Full Text] [Related]
15. Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients.
Jamali R; Pourhassan S; Maghbouli N; Ashraf H; Sohrabpour AA
Med J Islam Repub Iran; 2020; 34():135. PubMed ID: 33437731
[No Abstract] [Full Text] [Related]
16. Per- and Polyfluoroalkyl Substances and Obesity, Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: A Review of Epidemiologic Findings.
Qi W; Clark JM; Timme-Laragy AR; Park Y
Toxicol Environ Chem; 2020; 102(1-4):1-36. PubMed ID: 33304027
[TBL] [Abstract][Full Text] [Related]
17. The association of a healthy lifestyle index and imaging-based body fat distribution with glycemic status and Type 2 diabetes in the Multi Ethnic Cohort: a cross-sectional analysis.
Klapp R; Nimptsch K; Pischon T; Wilkens LR; Lim U; Guillermo C; Setiawan VW; Shepherd JA; Le Marchand L; Maskarinec G
Eur J Clin Nutr; 2024 Mar; 78(3):236-242. PubMed ID: 38097807
[TBL] [Abstract][Full Text] [Related]
18. Using Bayesian networks with tabu algorithm to explore factors related to chronic kidney disease with mental illness: A cross-sectional study.
Yuan X; Song W; Li Y; Wang Q; Qing J; Zhi W; Han H; Qin Z; Gong H; Hou G; Li Y
Math Biosci Eng; 2023 Aug; 20(9):16194-16211. PubMed ID: 37920009
[TBL] [Abstract][Full Text] [Related]
19. Quantitative imaging reveals steatosis and fibro-inflammation in multiple organs in people with type 2 diabetes: a real-world study.
Diamond C; Pansini M; Hamid A; Eichert N; Pandya P; Ali SN; Kemp GJ; Thanabalasingham G; Thomaides Brears HB; Cuthbertson DJ
Diabetes; 2024 May; ():. PubMed ID: 38748492
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of the impact of public health policies on obesity and lifetime risk of type 2 diabetes: A modelling approach.
Bauvin P; Delacôte C; Wandji LCN; Lassailly G; Raverdy V; Pattou F; Deuffic-Burban S; Mathurin P
PLoS One; 2024; 19(3):e0301463. PubMed ID: 38547299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
